Strategic report Governance & remuneration Financial statements Investor information 38 Acquisitions and disposals Details of the acquisition and disposal of significant subsidiaries and associates, joint ventures and other businesses are given below: 2015 Acquisitions Novartis Consumer Healthcare and Vaccines businesses The three-part inter-conditional transaction with Novartis AG involving the Consumer Healthcare, Vaccines and Oncology businesses completed on 2 March 2015.
GSK and Novartis have contributed their respective Consumer Healthcare businesses into a Consumer Healthcare Joint Venture in a non-cash transaction.
GSK has an equity interest of 63.5% and majority control of the Joint Venture.
In addition, GSK has acquired Novartis global Vaccines business excluding inuenza vaccines for an initial cash consideration of $5.25 billion 3.417 billion with contingent consideration representing subsequent potential milestone payments of up to $1.8 billion 1.2 billion arising on the achievement of specified development targets and ongoing royalties based on the future sales performance of certain products, and so the total amount payable is unlimited.
The first milestone of $450 million 300 million was paid on 26 March 2015.
Other business acquisitions In addition, GSK completed one smaller Vaccines business acquisition for cash consideration of 120 million, net of cash acquired, and the fair value of existing investments of 15 million.
This represented goodwill of 22 million and intangible assets of 124 million less other net liabilities of 11 million.
The fair values of the assets acquired in business combinations, including goodwill, are set out in the table below.
These amounts are provisional and subject to change.
Novartis Consumer Novartis Healthcare Vaccines business business Other m m m Net assets acquired: Intangible assets 6,003 2,680 124 Property, plant and equipment 249 434 1 Inventory 257 347 Trade and other receivables 400 162 2 Other assets including cash and cash equivalents 304 283 19 Trade and other payables 402 107 3 Deferred tax liabilities 1,154 78 26 Other liabilities 165 299 5,492 3,422 117 Non-controlling interest 2,150 19 Goodwill 774 576 22 4,116 3,979 139 Consideration settled by shares in GSK Consumer Healthcare Holdings 4,116 Cash consideration paid after purchase adjustments 3,461 124 Fair value of equity investment disposal 15 Contingent consideration 594 Deferred tax on contingent consideration 52 Loss on settlement of pre-existing relationships 24 Total consideration 4,116 3,979 139 The non-controlling interest in the Consumer Healthcare Joint Venture, calculated applying the full goodwill method, represents Novartis share of the net assets of the Joint Venture together with attributable goodwill.
The goodwill in the businesses acquired represents the potential for further synergies arising from combining the acquired businesses with GSKs existing businesses together with the value of the workforce acquired.
The majority of the goodwill recognised is not expected to be deductible for tax purposes.
Total transaction costs recognised in 2014 and 2015 for the acquisitions from Novartis amounted to 102 million.
Since acquisition on 2 March 2015, turnover of 1,941 million arising from the Novartis Consumer Healthcare and Vaccines businesses has been included in Group turnover.
If the businesses had been acquired at the beginning of the year, it is estimated that Group turnover in 2015 would have been approximately 320 million higher.
These businesses have been integrated into the Groups existing activities and it is not practicable to identify the impact on the Group profit in the period.
Disposals Oncology GSK has divested its marketed Oncology business, related R&D activities and rights to its AKT inhibitor and also granted commercialisation partner rights for future oncology products to Novartis for consideration of $16 billion 10,395 million before purchase adjustments.
GSK Annual Report 2015 185 Strategic report Governance & remuneration Financial statements Investor information Notes to the financial statements continued 38 Acquisitions and disposals continued Other business disposals GSK also made a number of small business disposals in the period for net cash consideration of 309 million.
profit on disposal of the businesses has been determined as follows: Oncology Other m m Cash consideration including currency forwards and purchase adjustments 10,060 309 Net assets sold: Goodwill 497 14 Intangible assets 516 107 Property, plant and equipment 25 Inventory 51 Cash 5 Other net assets 6 1,013 208 Loss on currency forwards booked in 2014 299 Disposal costs 118 21 profit on disposal 9,228 80 Investments in associates and joint ventures In March 2015, GSK sold half of its shareholding in Aspen, representing 6.2% of the issued share capital of the company, for 571 million in cash.
As a result of the sale, the Group was no longer considered to have the ability to exert significant inuence over Aspen and the Groups remaining investment was transferred from Investments in associates to Other investments.
m Cash consideration 571 Net book value of shares 143 Reclassication of exchange from other comprehensive income 30 Transaction fees 7 Other items 5 profit on disposal 386 Associates Business Business and JV acquisitions disposals disposals Total Cash ows m m m m Cash consideration paid received after purchase adjustments 3,585 10,369 571 7,355 Cash and cash equivalents acquired divested 404 5 399 Deferred cash proceeds 38 38 Contingent consideration paid 338 338 Transaction costs and other 22 80 7 109 Cash outow inow in 2015 3,541 10,246 564 7,269 In addition, GSK made cash investments of 16 million into associates and joint ventures.
Contingent consideration payable The consideration for certain acquisitions includes amounts contingent on future events such as development milestones or sales performance.
The Group has provided for the fair value of this contingent consideration as follows: ShionogiViiV Novartis Healthcare Vaccines Other Total m m m m At 1 January 2014 923 1 924 Remeasurement through goodwill 4 4 Remeasurement through income statement 768 2 770 Settlement 7 41 34 At 31 December 2014 1,684 40 1,724 Additions through business combinations 594 594 Remeasurement through income statement 1,874 111 1 1,986 Settlement 159 300 459 Other movements 10 10 At 31 December 2015 3,409 405 41 3,855 306 million of the contingent consideration payable at 31 December 2015 is expected to be paid within one year 2014 105 million.
The consideration payable for the acquisition of the Shionogi-ViiV Healthcare joint venture and the Novartis Vaccines business is expected to be paid over a number of years.
Information on the sensitivity of the income statement and balance sheet to reasonably possible changes in key inputs to the valuations of the contingent consideration payable for the Shionogi-ViiV Healthcare business and Novartis Vaccines business is provided in Note 41, Financial instruments and related disclosures.
186 GSK Annual Report 2015 Strategic report Governance & remuneration Financial statements Investor information 38 Acquisitions and disposals continued During 2015, cash payments to settle the Shionogi-ViiV Healthcare joint venture contingent consideration payable amounted to 159 million in total, of which 121 million was reported in operating cash ows and 38 million in the cash ow for purchases of business.
2014 Acquisitions There were no acquisitions in 2014.
Acquisition and integration costs of 141 million arising on the proposed three-part inter-conditional transaction with Novartis AG were expensed in 2014, of which 104 million was paid in cash in the year.
Disposals During the year, 225 million was received as deferred consideration from the sale of the anti-coagulant business completed in 2013 and 1 million from the disposal of an associate.
GSK also made cash investments of 9 million into associates.
Business Associates acquisitions and joint and disposals ventures Total Cash ows m m m Cash consideration paid 99 Transaction costs paid 104 104 Purchases of businesses and associates 104 9 113 Net cash proceeds from disposals 225 1 226 2013 Acquisitions During 2013, GSK completed the acquisition of three businesses for cash, including Okairos AG, a European based biopharmaceutical company focused on the development of a specic vaccine technology in the prophylactic and therapeutic elds, which was acquired in May.
The total purchase price for these businesses of 255 million included 7 million of cash acquired and 1 million of contingent consideration.
Fair value m Net assets acquired Intangibles 198 Property, plant and equipment 23 Inventory 6 Trade and other receivables 16 Other assets including cash and cash equivalents 8 Deferred tax provision 23 Trade and other payables 26 202 Goodwill 53 255 Cash consideration paid 254 Contingent consideration 1 Total consideration 255 If the acquisitions had been made at the beginning of the year, it is estimated that Group turnover would have increased by approximately 50 million for the year.
Okairos has been fully integrated into the GSK business and it is not practicable to separately identify the impact on the Group profit for the year.
The other acquisitions occurred shortly before the end of the year and had no material impact on the Group profit for the year.
The goodwill arising on the acquisitions reects potential for business synergies and the value of workforce acquired.
The majority of this goodwill is not expected to be deductible for income tax purposes.
The results of the acquisitions are reported within the US, Europe, Emerging Markets, Japan, Other trading and unallocated Pharmaceuticals and Vaccines and Consumer Healthcare operating segments.
The transactions were accounted for using the acquisition accounting method.
Acquisition costs expensed in 2013 totalled 2 million.
GSK Annual Report 2015 187 Strategic report Governance & remuneration Financial statements Investor information Notes to the financial statements continued 38 Acquisitions and disposals continued Disposals Lucozade and Ribena On 31 December 2013, GSK completed the sale of the Lucozade and Ribena business including a manufacturing site and related inventory to Suntory Beverage and Food Ltd for 1,352 million in cash and recognised a profit on disposal in Other operating income of 1,057 million.
Lucozade and Ribena sales, excluding retained markets, totalled 527 million for the year ending 31 December 2013. m Cash consideration 1,352 Net assets sold: Inventory 45 Property, plant and equipment 149 Goodwill 24 218 Disposal costs 77 profit on disposal 1,057 Anti-coagulant business On 31 December 2013, GSK completed the sale of the anti-coagulant business comprising of worldwide intellectual property rights excluding China, India and Pakistan of Fraxiparine and Arixtra together with related inventory and a manufacturing site to the Aspen Group for consideration of 732 million, of which 499 million was received in cash and 233 million was deferred.
profit on disposal of 274 million was recognised in Other operating income.
Worldwide sales of Fraxiparine and Arixtra, excluding retained markets, were 345 million for the year ending 31 December 2013. m Cash consideration 499 Cash consideration receivable 233 732 Net assets sold: Inventory 138 Property, plant and equipment 91 Intangible assets 80 Goodwill 31 340 Disposal costs 79 Total profit on disposal 313 Deferral of profit 39 profit recognised in year 274 Investments in associates and joint ventures In November 2013, GSK sold one third of its shareholding in Aspen, representing 6.2% of the issued share capital of the company, for 429 million in cash.
At 31 December 2013, GSK held 12.4% of Aspen and continued to recognise its investment in Aspen as an associate.
m Cash consideration 429 Net book value of shares 132 Reclassication of exchange from other comprehensive income 42 Reclassication of fair value movements from other comprehensive income 19 profit on disposal 274 188 GSK Annual Report 2015
